The TRIPS Trap: Industry’s Delicate Challenge Responding To Waiver Push
Executive Summary
Biopharma companies are understandably upset by the Biden Administration’s decision to support a waiver of intellectual property protections on COVID vaccines. But over-reacting may only make matters worse.